Emtricitabine

Generic Name
Emtricitabine
Brand Names
Atripla, Biktarvy, Complera, Descovy, Emtriva, Genvoya, Odefsey, Stribild, Truvada
Drug Type
Small Molecule
Chemical Formula
C8H10FN3O3S
CAS Number
143491-57-0
Unique Ingredient Identifier
G70B4ETF4S
Background

Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) indicated for the treatment of HIV infection in adults or combined with tenofovir alafenamide for the prevention of HIV-1 infection in high risk adolescents and adults. Emtricitabine is a cytidine analogue. The drug works by inhibiting HIV reverse transcriptase, preventing transcription of ...

Indication

Emtricitabine is indicated in combination with other medications for the treatment of HIV-1 infections; treatment of HIV-1 infections in pediatric patients 25-35kg, treatment of HIV-1 infections in adult patients ≥35kg, for pre exposure prophylaxis of HIV-1 in adolescent and adult patients excluding those who have receptive vaginal sex; treatment of HIV-1 in...

Associated Conditions
HIV Transmission, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Associated Therapies
Pre-Exposure Prophylaxis (PrEP)
Clinical Trials
Related News

Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults

First Posted Date
2008-02-06
Last Posted Date
2018-10-12
Lead Sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Target Recruit Count
529
Registration Number
NCT00608569
Locations
🇺🇬

JCRC CRS, Kampala, Uganda

🇭🇹

Les Centres GHESKIO CRS, Bicentenaire, Port-au-Prince, Haiti

🇵🇪

Barranco CRS, Lima, Peru

and more 6 locations

Characterization of Acute and Recent HIV-1 Infections in Zurich.

First Posted Date
2007-10-02
Last Posted Date
2024-12-17
Lead Sponsor
University of Zurich
Target Recruit Count
800
Registration Number
NCT00537966
Locations
🇨🇭

University of Zurich, Zurich, Switzerland

Efficacy of Tenofovir and Emtricitabine in ARV-naive Patients With HIV/HBV Co-infection

Phase 2
Completed
Conditions
Hepatitis B Virus
HIV Infections
Interventions
Drug: Emtricitabine
First Posted Date
2007-05-22
Last Posted Date
2016-02-22
Lead Sponsor
The HIV Netherlands Australia Thailand Research Collaboration
Target Recruit Count
24
Registration Number
NCT00476463
Locations
🇹🇭

HIV-NAT Thai Red Cross AIDS Research Center, Bangkok, Thailand

Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A

First Posted Date
2006-09-25
Last Posted Date
2023-08-14
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
4
Registration Number
NCT00380159
Locations
🇪🇸

Clinical Trial Site, Madrid, Spain

Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection

Phase 4
Completed
Conditions
HIV Infections
Hepatitis B
First Posted Date
2005-08-09
Last Posted Date
2007-04-24
Lead Sponsor
International Antiviral Therapy Evaluation Center
Target Recruit Count
24
Registration Number
NCT00127959
Locations
🇳🇱

Academic Medical Center, Amsterdam, NH, Netherlands

Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129)

Phase 3
Completed
Conditions
HIV Infections
Tuberculosis
First Posted Date
2005-06-24
Last Posted Date
2011-12-22
Lead Sponsor
French National Agency for Research on AIDS and Viral Hepatitis
Target Recruit Count
70
Registration Number
NCT00115609
Locations
🇫🇷

Service des maladies Infectieuses et tropicales Hopital Necker-Enfants Malades, Paris, France

A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy

Phase 2
Completed
Conditions
HIV Infections
First Posted Date
2005-01-26
Last Posted Date
2021-11-01
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
6
Registration Number
NCT00102206
Locations
🇺🇸

Columbia IMPAACT CRS, New York, New York, United States

🇺🇸

Chicago Children's CRS, Chicago, Illinois, United States

🇺🇸

SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States

and more 1 locations

NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission

First Posted Date
2004-08-06
Last Posted Date
2018-10-12
Lead Sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Target Recruit Count
745
Registration Number
NCT00089505
Locations
🇿🇦

University of Witwatersrand, Johannesburg, South Africa

🇧🇼

The Gaborone BHP Study Clinic, Bontleng, Gaborone, Botswana

🇿🇲

Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia

and more 8 locations

Three Month Course of Anti-HIV Medications for People Recently Infected With HIV

Not Applicable
Withdrawn
Conditions
HIV Infections
First Posted Date
2004-07-13
Last Posted Date
2021-11-01
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Registration Number
NCT00087464

Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings

First Posted Date
2004-06-08
Last Posted Date
2018-10-10
Lead Sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Target Recruit Count
1571
Registration Number
NCT00084136
Locations
🇺🇸

University of Texas, Galveston, Galveston, Texas, United States

🇲🇼

College of Med. JHU CRS, P.O. Box 1131, Blantyre, Malawi

🇿🇼

UZ-Parirenyatwa CRS, AIDS Research Unit P.O. Box A178, Harare, Zimbabwe

and more 39 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy